ARAMIS does look encouraging and is one of many drug candidate that are Androgen Regulators. The efficacy of other Androgen regulators looks very promising for prostate cancer sufferers.
I am invested in a company called Valirx who also have Castration Resistant Prostate Cancer Therapuetic in Clinical Trial - https://clinicaltrials.gov/ct2/show/NCT02280317?term=valirx&rank=1
It's a big week for Valirx as the first formal efficacy data is expected to be announced before the end of June. From then they are also going to target Breast, Ovarian cancers and Endometrisos. As a laymen I find it fascinating to see just how prevalent hormones are in cancer ocurrances and the strength of them.
The trial is still open for recruitment at UCLH
VAL 201 is unique among AR blockers/regulators in that it allows normal and desirable androgen function, and thus avoids side effects such as feminisation and sexual dysfunction. Thus far they have had no adverse reactions whatsoever.
How 201 works
You also have to understand the science behind VAL201 and what it does. In Breast and Prostate Cancer, the Androgen Receptor binds with Src stimulating Src kinase activity. This causes Cancer Cells to grow. VAL201 blocks the entry for the AR, so that it can't bind to the Src, thus the Cancer cells can't grow. Think of 201 as a barrier, a blocking agent that stops Prostate Cancer Cells from 'docking', thus stops cancerous cells from spreading. Pre-clinical evidence shows this will work in similar genetic types. As long as it does, efficacy just isn't an issue, there is no way the cells can spread. Remember those preclinical results were quite exceptional, they stopped tumor growth. While the trial is on terminally ill patients who will likely die from their Cancer whether they take this trial or not, if it stops their tumor growing, it will be of major assistance to those where Prostate and Breast Cancer is noticed earlier. People could end up just living with their tumors and taking this treatment,